Abstract
Pleuropulmonary blastoma (PPB) is a rare cancer occurring mainly during early childhood and often associated with germline DICER1 mutations. It is classified by the macroscopic appearance into three interrelated clinico-pathologic entities on a developmental continuum. Complete tumor resection is a main prognostic factor and can be performed at diagnosis or after neoadjuvant treatment that includes chemotherapy and in some cases radiotherapy. Optimal modalities of neo- or adjuvant treatments can be challenging taking into account potential long-term toxicities in this young population. This paper presents the recommendations for diagnosis and treatment of children and adolescents with PPB elaborated by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the European Union-funded project PARTNER (Paediatric Rare Tumours Network - European Registry).
Author supplied keywords
Cite
CITATION STYLE
Bisogno, G., Sarnacki, S., Stachowicz-Stencel, T., Minard Colin, V., Ferrari, A., Godzinski, J., … Orbach, D. (2021). Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer, 68(S4). https://doi.org/10.1002/pbc.29045
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.